During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in ...

A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

A study by UCO's Department of Agricultural Economics, Finance and Accounting identifies stability and flexibility as the two ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Domestic researchers have found for the first time in the world that immuno-cancer drugs atetzolizumab plus bevacizumab ...

A new review urges oncology researchers to treat patient-reported outcomes as core trial endpoints — not just secondary stats ...

Scancell Holdings plc (AIM: SCLP), the developer of Immunobody ® and Moditope ® active immunotherapies to treat cancer, announces further positive data from the ongoing Phase 2 SCOPE trial of ...

AstraZeneca Plc. announced on Monday that it plans to invest $50 billion in the U.S. by 2030, with a focus on expanding drug ...

AstraZeneca's Tagrisso with chemo significantly improves survival and progression-free outcomes in EGFR-mutant NSCLC, final trial data shows.

The study will compare neladalkib to Genentech's ALK inhibitor Alecensa in patients who've had no prior systemic treatment.

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.